Healthcare stocks that created a buzz today!

The S&P/ASX200 closed up Tuesday, gaining 67.20 points or 0.92% to 7379.50 and setting a new 100-day high. Over the last five days, the index has gained 1.19% and is currently 0.26% off of its 52-week high.

10 of 11 sectors have ended higher along with the S&P/ASX 200 Index. Health Care was the best performing sector, gaining 1.96% and 2.83% for the past five days.

Also read: ASX closes at a record high amid blue-chip rally

Few healthcare stocks that created a buzz today were.

Zelira (ASX:ZLD) to launch CBD toothpaste in the UK, shares end bullish

Zelira Therapeutics Ltd (ASX:ZLD) shared today that it will be launching CBD toothpaste in the United Kingdom via exclusive distribution agreement with Health House International.

Key highlights:

  • Zelira is expanding distribution of hemp derived CBD oral care products to the UK through an exclusive distribution agreement with Health House International.
  • Health House International will be purchasing and exclusively distributing a minimum US$250,000 of Zelira’s CBD Toothpaste over the first six months of the agreement, and a further US$250,000 over the second six months.
  • UK launch is a key milestone in Zelira’s global growth strategy into new geographies and consumer product segments.

Meanwhile, the stock ended 2.127% higher at AU$0.048 per share.

Image Source: © Tinyakovs |

Australia's CSL climbs over A$300 for the first time in 2021

Australian biotech firm CSL Limited (ASX:CSL) is back to over AU$300 for the first time this year. 

CSL, Australia's priciest stock, clocked up to 2.4% gains and reached to a level of AU$303.79 - its highest since 10 December 2020.

As per the Company’s announcement, CSL’s influenza vaccine company, Seqirus, and Novavax have co-authored the first study on administering a COVID-19 vaccine with a seasonal influenza shot.

CSL is making the AstraZeneca COVID-19 vaccine in Australia, churning out around a million doses a week. It is contracted to make 50 million doses in total.

Meanwhile, the stock closed 1.877% higher at AU$302.210 per share today.

Do Read: How has the Coles Group share price performed in CY2021?

Japara Healthcare (ASX:JHC) hits near two-year peak on rival A$251 million buyout proposal

Japara Healthcare Limited (ASX:JHC) gained as much as 5.1% to AU$1.240, hitting its highest since 16 September 2019.

The aged-care facilities operator shared that it has received a buyout proposal from not-for-profit home-care provider RSL Care RDNS Limited, part of the Bolton Clarke Group, valued at AU$326 million.

Latest offer is at a 3.4% premium to stock's last close and 1.7% premium to offer from Little Company of Mary Healthcare Ltd announced last week.

JHC Board stated that it is appropriate to offer Bolton Clarke due diligence access so it can develop a binding proposal.

More than 980,000 shares have been traded so far, as compared with the 30-day average volume of about 684,000.

The stock is up 90% this year, as of the last close and ended Tuesday’s session at AU$1.275 per share, up 8.050%.

Must Read: Argenica Therapeutics (ASX:AGN) shares surge ~30% on Day 1 on the ASX

Image Source: © Niderlander |

Argenica Therapeutics (ASX:AGN) begins trading on ASX

Argenica Therapeutics (ASX:AGN), now listed on the ASX for trading on 11 June 2021, recorded $7 million capital raising. The capital was raised at AU$0.20 per share with a market capitalisation of AU$14.6 million.

The Company is developing novel therapeutics to potentially reduce brain tissue death after a stroke, improve patient outcomes and reduce long-term healthcare costs. There is currently no marketed treatment available for protecting brain damage caused by stroke. Argenica aims to become a foundational company within this space.

Argenica’s lead neuroprotective peptide candidate, ARG-007, has already successfully demonstrated improved outcomes in pre-clinical stroke models. AGN will direct funds from the IPO towards the first Phase I in-human clinical trial.

AGN shares closed at AU$0.215, down 17.308%.

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK